These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7140941)

  • 21. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients.
    Boneu B; Destelle G
    Thromb Haemost; 1996 Dec; 76(6):939-43. PubMed ID: 8972014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Structural aspects of the kidney in experimental atheromatosis].
    Lasierra J; Sánchez Casajús A; Martínez Peñuela JM; Velázquez E
    Rev Clin Esp; 1984 Apr; 173(1):15-9. PubMed ID: 6739892
    [No Abstract]   [Full Text] [Related]  

  • 23. Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine.
    Bastida E; Escolar G; Almirall L; Ordinas A
    Thromb Haemost; 1986 Jun; 55(3):333-7. PubMed ID: 3750263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function.
    Picard-Fraire C
    Agents Actions Suppl; 1984; 15():68-75. PubMed ID: 6385655
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacological studies on ticlopidine, a new platelet aggregation inhibitor. Part I: Cardiovascular effects.
    Akashi A; Tamura K; Hirohashi M; Watanabe K; Kasahara A
    Arzneimittelforschung; 1980; 30(3):409-14. PubMed ID: 7387750
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
    Kohga S; Kinjo M; Tanaka K; Ogawa H; Ishihara M; Tanaka N
    Cancer Res; 1981 Nov; 41(11 Pt 1):4710-4. PubMed ID: 7306988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hematological toxicity of ticlopidine? (author's transl)].
    de Gramont A; Canuel C; Krulik M; Bauters F; Degos L; Marty M; Najean Y
    Nouv Rev Fr Hematol (1978); 1982; 24(1):35-7. PubMed ID: 7071010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Migraine or transient ischemic attacks in a patient with essential thrombocythaemia. Treatment with ticlopidine (author's transl)].
    Bousser MG; Conard J; Lecrubier C; Bousser J
    Ann Med Interne (Paris); 1980; 131(2):87-90. PubMed ID: 7396326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Problems of the elderly patient in anticoagulant and platelet-suppressant drug treatment].
    Nagakawa Y; Matsushita S
    Nihon Ronen Igakkai Zasshi; 1986 Jul; 23(4):372-8. PubMed ID: 3784093
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effects of ticlopidine on blood circulation and thrombin-induced platelet aggregation in experimental diabetic rats- and it's efficacy for remedy of diabetic retinopathy (author's transl)].
    Fujie K; Fujie Y
    Nippon Ganka Gakkai Zasshi; 1981 Mar; 85(3):242-9. PubMed ID: 7270347
    [No Abstract]   [Full Text] [Related]  

  • 31. A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study.
    Nyberg G; Larsson O; Westberg NG; Aurell M; Jagenburg R; Blohmé G
    Clin Nephrol; 1984 Mar; 21(3):184-7. PubMed ID: 6705280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Platelet antiaggregants and bleeding time lengthening: management in the preoperative period].
    Thébault JJ; Blatrix C; Blanchard J; Panak E
    Agressologie; 1983 Dec; 24(12):609-11. PubMed ID: 6670692
    [No Abstract]   [Full Text] [Related]  

  • 33. [Platelet aggregation inhibitors].
    Castaigne A; Benghozi R; Bienvenu MP
    Rev Infirm; 1981 Dec; 31(19):45-8. PubMed ID: 6977177
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of oral ticlopidine on arachidonic acid products in human platelets.
    Bruno JJ; Chang LF; McSpadden MM; Yang D
    Agents Actions Suppl; 1984; 15():76-87. PubMed ID: 6435408
    [No Abstract]   [Full Text] [Related]  

  • 35. [Ticlopidine and platelet function].
    Camici M; Evangelisti L
    Minerva Med; 1992 Sep; 83(9):525-8. PubMed ID: 1436601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Use of a new platelet aggregation inhibitor, ticlopidine, in hemodialysis].
    Griffanti-Bartoli F; Altomonte F; Pitton L; Armani U; Piana A
    Arch Maragliano Patol Clin; 1979; 35(2):73-80. PubMed ID: 263724
    [No Abstract]   [Full Text] [Related]  

  • 37. Ex vivo effects of ticlopidine on human platelets: inhibition of fibrinogen binding by a mechanism independent of thromboxane formation.
    Iovine C; d'Avenia V; Turco S; Mattioli PL; di Minno G
    Agents Actions Suppl; 1984; 15():105-7. PubMed ID: 6592941
    [No Abstract]   [Full Text] [Related]  

  • 38. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.
    Ashida SI; Abiko Y
    Thromb Haemost; 1979 Apr; 41(2):436-49. PubMed ID: 224522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mechanism of platelet aggregation inhibition].
    Abiko Y; Ashida S
    Rinsho Byori; 1979; Suppl 40():169-80. PubMed ID: 233105
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.